# Safi Biotherapeutics Awarded a $4.7 Million Extension by U.S. DoW to Advance Manufactured Red Blood Cells Toward First Clinical Trial

- Source: PR Newswire M&A
- Published: 2026-11-03T13:00:00+00:00
- Category: Business
- Original: https://www.prnewswire.com/news-releases/safi-biotherapeutics-awarded-a-4-7-million-extension-by-us-dow-to-advance-manufactured-red-blood-cells-toward-first-clinical-trial-302926878.html
- Canonical: https://groundlevelnews.com/story/safi-biotherapeutics-awarded-a-4-7-million-extension-by-u-s-dow-to-adv-b4aabc/

Award funds the final IND-enabling work needed prior to initiating Safi's first clinical trial CAMBRIDGE, Mass., Nov. 3, 2026 /PRNewswire/ -- Safi Biotherapeutics, a company that manufactures stem-cell derived human red blood cells (mRBCs) as a dual-use product for civilian and military...

_Ground Level News shows a short summary only; the full article and all rights belong to PR Newswire M&A._